GlaxoSmithKline's backing what it describes as a "cutting edge" player in the race to develop a Covid-19 vaccine.

The Brentford-based drug giant's putting 130-million pounds into German company CureVac for 10-percent of the business.

The treatment involves getting the immune system to produce a protein to fight the virus.